Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib + Chemotherapy in TNBC
NCT04762901Phase 1Withdrawn
- Sponsor
- Wake Forest University Health Sciences
- Start
- Apr 2021
- Primary completion
- Jan 2026
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of niraparib in triple-negative breast cancer (TNBC) (6 arms), sponsored by Wake Forest University Health Sciences. Primary endpoints: Dose-Limiting Toxicities at 28 days and Clinically Significant Toxicities at 84 days. Planned start Apr 2021; status: withdrawn.
02
Drugs
niraparib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04762901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04762901.